The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1614
ISSUE 1614
December 28, 2020
Ofatumumab (Kesimpta) for Multiple Sclerosis
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
December 28, 2020 (Issue: 1614)
The FDA has approved a subcutaneous formulation
of the recombinant human anti-CD20 antibody
ofatumumab (Kesimpta – Novartis) for treatment
of adults with relapsing forms of multiple sclerosis
(MS), including clinically isolated syndrome (initial
neurological episode), relapsing-remitting disease,
and active secondary progressive MS (SPMS).
Kesimpta is the second anti-CD20 antibody to be
approved for these indications; IV ocrelizumab
(Ocrevus), which is also approved for treatment
of primary progressive MS, was the first. An IV
formulation of ofatumumab (Arzerra) has been
available for treatment of chronic lymphocytic
leukemia (CLL) since 2010.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Ofatumumab (Kesimpta) for Multiple Sclerosis
Article code: 1614c
Electronic, downloadable article - $45
Article code: 1614c
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
